Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Treatment Study of Elotuzumab in Multiple Myeloma
2016-000037-51Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Treatment exposure. Started May 2020; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-000037-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000037-51.